

**THE VALUE OF BIOMARKERS,  
NEUROPHYSIOLOGY AND NEUROPSYCHOLOGY  
IN DIAGNOSIS AND PROGNOSIS OF  
MESIAL TEMPORAL SCLEROSIS**

**Thesis**

Submitted for Partial Fulfillment of the Doctorate Degree (M.D.) in  
**NEUROLOGY**

By

***HEBATALLA SAHER ELSAYED HASHEM***

(M.B, B.Ch, M.Sc Neuropsychiatry, Cairo University)  
Assistant Researcher, National Research Center

Supervised by

**PROF. DR. FAROUK KOURA**

*Professor of Neurology,  
Faculty of Medicine, Cairo University*

**PROF. DR. NAGWA A MEGUID**

*Professor of Human Genetics,  
National Research Center*

**PROF. DR. HATEM SAMIR**

*Professor of Neurology,  
Faculty of Medicine, Cairo University*

**PROF. DR. MONA ANWAR**

*Professor of Biochemistry,  
National Research Center*

**FACULTY OF MEDICINE  
CAIRO UNIVERSITY**

**2014**

## تقرير جماعي

لجنة المناقشة و الحكم علي رسالة الدكتوراة المقدمة من الطيبية هبة الله ساهر السيد هاشم  
توطئة للحصول علي درجة الدكتوراة في الامراض العصبية و المشكلة بقرار من مجلس الكلية  
و المعتمد من السيد الاستاذ الدكتور نائب رئيس الجامعة للدراسات العليا

و تتكون لجنة الحكم من:

ا.د. فاروق قورة استاذ الامراض العصبية - جامعة القاهرة عن المشرفين

ا.د. حسن حسني- استاذ الامراض العصبية - جامعة القاهرة (م.داخلي)

ا.د. سامية عاشور - استاذ الامراض العصبية - جامعة عين شمس (ممتحن خارجي)

و ذلك بمشيئة الله تعالى يوم الاثنين الموافق ٢٠١٤/٢/٣ و ذلك بقاعة المؤتمرات  
بكلية الطب - القصر العيني - جامعة القاهرة



و شملت الدراسة :- القيمة التشخيصية و التنبؤية للمؤشرات الحيوية و الفسيولوجيا العصبية  
و الاختبارات النفسية في حالات تصلب الفص الصدغي

قررت اللجنة بعد المناقشة :

ا.د. سامية عاشور

ا.د. حسن سعد حسني

ا.د. فاروق محمد قورة



---

**بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ**

## ACKNOWLEDGMENT

*Thank You GOD for everything*

*My father Prof. Dr. SAHER HASHEM, My Mother Dr. HALA FARID, my family ... with your unconditional love and support, you leave me speechless, can't thank you enough.*

*I am honored and privileged to have Prof. Dr. FAROUK KOURA, Professor of Neurology, Cairo University, as my supervisor, Sir you are an idol and words are not enough to thank you for all the support.*

*I would like to deeply thank my dear Prof. Dr. NAGWA A. MEGUID, Professor of Human Genetics, National Research Center, for her continuous guidance, care and support. Thank You for everything.*

*I would like to express my sincere gratitude to Prof. Dr. HATEM SAMIR, Professor of Neurology, Cairo University, for his fruitful criticism and helping me throughout the entire work.*

*I take this opportunity to express my deepest regards to Prof. Dr. MONA ANWAR, Professor of Biochemistry, National Research Center, for her meticulous eye, continuous support and efforts.*

*I would also like to thank Dr. ADEL HASHISH, Researcher, National Research Center, for his contribution to this work and for his willingness to help.*

*Special Thanks to my colleague and friend, Dr. REHAB KHALIL, Researcher, National Research Center, for her support and unrelenting efforts to help me throughout my work.*

*I am obliged to Staff Members of Epilepsy Clinic at Kasr El-Aini Hospitals and my colleagues at the National Research center for their support and help.*

*Lastly, My Grandpa Prof. FARID ROAIAH, Prof. Dr. OSAMA ELWAN and Prof Dr. OSAMA BARRADA, you are greatly missed and I so wished to have you with me on this day . I know you would have been glad. May your souls rest in peace.*

*DEDICATED*

---

*TO MY FAMILY*

---

	<b>Page</b>
▪ <b>INTRODUCTION</b> .....	1
▪ <b>AIM OF THE WORK</b> .....	3
▪ <b>REVIEW OF LITERATURE</b> .....	4
○ Epidemiology of temporal lobe epilepsy .....	4
○ Anatomy of hippocampus .....	5
○ Neuropathology of temporal lobe epilepsy .....	9
○ Mesial temporal sclerosis and epilepsy .....	12
○ Inflammation and Mesial temporal lobe epilepsy .....	18
○ Genetics of Mesial temporal lobe epilepsy .....	22
○ Semiology of temporal lobe epilepsy .....	25
○ Electroencephalographic findings .....	31
○ Biomarkers .....	33
▪ Matrix metalloproteinase-9 .....	35
▪ Prolactin .....	41
▪ C-reactive protein .....	42
▪ S100B calcium binding protein .....	43
○ Temporal lobe epilepsy and cognition .....	47
○ Neuroimaging .....	49
○ Prognosis of Mesial temporal lobe epilepsy .....	53
○ Co-morbidities .....	54
▪ <b>SUBJECTS AND METHODS</b> .....	56
▪ <b>RESULTS</b> .....	68
▪ <b>CASE PRESENTATION</b> .....	94
▪ <b>DISCUSSION</b> .....	98
▪ <b>SUMMARY AND CONCLUSIONS</b> .....	110
▪ <b>RECOMMENDATIONS</b> .....	112
▪ <b>REFERENCES</b> .....	113
▪ <b>APPENDIX</b> .....	140
▪ <b>ARABIC SUMMARY</b> .....	i

## **LIST OF TABLES**

<b>No.</b>	<b>Title</b>	<b>Page</b>
<b>1</b>	Ages of Cases and Controls	<b>68</b>
<b>2</b>	Sex Distribution among Cases and Controls	<b>69</b>
<b>3</b>	Handedness among Cases and Controls	<b>70</b>
<b>4</b>	Anthropometric Measurements among Cases and Controls	<b>72</b>
<b>5</b>	Age of first seizure	<b>72</b>
<b>6</b>	Seizure Duration	<b>73</b>
<b>7</b>	Prodrome, aura and automatism in Cases	<b>74</b>
<b>8</b>	Ictal semiology	<b>75</b>
<b>9</b>	Antiepileptic Medication	<b>77</b>
<b>10</b>	Psychometric testing: IQ, VSWM, MMSE.	<b>79</b>
<b>11</b>	Background activity of the long- term EEG	<b>79</b>
<b>12</b>	Long Term EEG findings	<b>80</b>
<b>13</b>	Serum levels of different biomarkers between cases and controls	<b>82</b>
<b>14</b>	Correlation between Gender and biomarkers	<b>85</b>
<b>15</b>	Correlation between the age of first fit, and duration of fits and serum levels	<b>86</b>
<b>16</b>	Side of MTS and Biomarkers	<b>87</b>
<b>17</b>	Correlation between seizure severity and Psychometric scales	<b>87</b>
<b>18</b>	Correlation between seizure severity and biomarkers	<b>90</b>
<b>19</b>	Correlation between bio-markers and psychometric tests	<b>91</b>
<b>20</b>	Correlation between age of first fit and duration of fits with cognition	<b>93</b>

**LIST OF FIGURES**

<b>No.</b>	<b>Title</b>	<b>Page</b>
<b>1</b>	A transverse section through the body of the hippocampus and dentate gyrus, choroid fissure, and inferior horn of the lateral ventricle	<b>8</b>
<b>2</b>	Tri synaptic organization of the hippocampus	<b>8</b>
<b>3</b>	Hippocampal sclerosis.	<b>10</b>
<b>4</b>	Pathophysiological cascade of inflammatory events in epilepsy	<b>21</b>
<b>5</b>	MMP9 Gene in genomic location	<b>37</b>
<b>6</b>	S100 b genomic location	<b>45</b>
<b>7</b>	Age in cases and controls	<b>69</b>
<b>8</b>	Sex distribution among cases and controls	<b>70</b>
<b>9</b>	Aura in Cases	<b>74</b>
<b>10</b>	Ictal semiology in Cases	<b>76</b>
<b>11</b>	AED	<b>78</b>
<b>12</b>	Long Term EEG findings	<b>80</b>
<b>13</b>	Side of MTS	<b>81</b>
<b>14</b>	CRP between Cases and Controls	<b>83</b>
<b>15</b>	S100 b levels between Cases and Controls	<b>83</b>
<b>16</b>	Serum levels of MMP9 between Cases and Controls	<b>84</b>
<b>17</b>	Prolactin levels between Cases and Controls	<b>84</b>
<b>18</b>	S100 b gender difference	<b>85</b>
<b>19</b>	Correlation between seizure severity and IQ	<b>88</b>
<b>20</b>	Correlation between seizure severity and MMSE	<b>88</b>
<b>21</b>	Correlation between seizure severity and VSMN	<b>89</b>
<b>22</b>	MMP9 and seizure severity	<b>90</b>
<b>23</b>	Correlation between MMP9 and IQ	<b>92</b>
<b>24</b>	Correlation between MMP9 and MMSE	<b>92</b>
<b>25</b>	Correlation between MMP9 and VSMN	<b>93</b>
<b>26</b>	Three generation Pedigree of case 1	<b>94</b>
<b>27</b>	MRI of case 1: bilateral hippocampal sclerosis	<b>95</b>
<b>28</b>	Long term EEG of case 1 : Bil frontotemporal spikes	<b>95</b>
<b>29</b>	Three generation Pedigree of case 2	<b>96</b>
<b>30</b>	MRI of case 2: Rt MTS	<b>97</b>
<b>31</b>	Long Term EEG of case 2 : Lft epileptiform discharges	<b>97</b>



## **ABBREVIATIONS**

ACTH	Adrenocorticotrophic hormone
AED	Antiepileptic drug
AEDs	Antiepileptic Drugs
BBB	Blood Brain Barrier
BDNF	Brain-derived neurotrophic factor
bMTLE	Benign mesial temporal lobe epilepsy
CA	Cornu Ammonis
CNS	Central Nervous System
CRP	C-reactive Protein
CSD	Cortical spreading depression
DG	Dentate Gyrus
DTI	Diffusion tensor imaging
EC	Entorhinal cortex
ECM	Extracellular Matrix
EEG	Electoencephalogram
FCD	Focal cortical dysplasia
FMTLE	Familial mesial temporal lobe epilepsy
FS	Febrile Seizures
HS	Hippocampal Sclerosis
ILAE	International League Against Epilepsy
IPI	Initial Precipitating Incident
IVIG	Intravenous immunoglobulin
LTP	Long-term potentiation
MF	Mossy Fibers
MMP9	Matrix Metalloproteinase 9

## ***ABBREVIATIONS***

---

MRI	Magnetic Resonance Imaging
MRS	Proton magnetic resonance spectroscopy
MTLE	Mesial Temporal Lobe Epilepsy
MTLE-HS	Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis
PTZ	Pentylentetrazole
RAGE	Receptor for Advanced Glycation End products
S100b	S100 calcium binding protein B
SE	Status Epilepticus
TBI	Traumatic Brain Injury
TIMPs	Tissue inhibitors of metalloproteinases
TIRDA	Temporal intermittent rhythmic delta activity
TLE	Temporal Lobe Epilepsy
VBM	Voxel-based morphometry

## **ABSTRACT**

Mesial temporal lobe epilepsy associated with hippocampal sclerosis is the most common form of partial epilepsy. **The aim of this work** is to find a suitable biomarker that can help with the diagnosis and prognosis of this intractable form of epilepsy. To achieve this aim, 30 patients with complex partial seizures and 30 controls with ages from 4-30 years were subjected to a battery of laboratory analysis including: S100B protein, Matrix Metalloproteinase 9, C-Reactive protein, prolactin, together with neurophysiological, radiological and psychometric assessments.

**Results:** A significant elevation was found in all the biomarkers between the cases and the controls. The performance of the epileptic patients in psychometric assessments were below average. MRI showed typical findings of MTS, EEG showed anterior temporal spikes. A significant negative correlation was found between MMP9 and psychometric test. Another significant negative correlation between seizure severity and biomarkers was found.

**Conclusion:** Serum biomarkers for neuronal injury are elevated with mesial temporal lobe epilepsy. Cognitive deficits are associated with mesial temporal lobe epilepsy.

### **KEYWORDS:**

Mesial temporal lobe epilepsy, Hippocampal sclerosis, S100B, MMP9, CRP, Prolactin, psychometric assessments

# INTRODUCTION

# INTRODUCTION

Epilepsy has been recognized since antiquity. It is one of the most common serious neurological conditions, affecting 0.4%–1.0% of the world population (**Treiman, 2010**).

Temporal lobe epilepsy (TLE) is the most common type of focal epilepsy syndromes in adults, representing approximately 60% of all partial epilepsies (**Téllez-Zenteno and Hernández-Ronquillo, 2012**).

Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis (MTLE-HS) is the most common form of focal epilepsy with a distinct clinical presentation called “limbic seizure” resulting from epileptic activity within the limbic structures. MTLE-HS syndrome is restricted to patients in whom hippocampal atrophy and/or abnormal signal intensity on Magnetic Resonance Imaging (MRI), and additional evidence of temporal dysfunction on functional images and neuropsychological assessment are demonstrated. MTLE usually presents between 6–10 years of age but can present from infancy to the 30s and affects 10 to 20% of children undergoing surgical treatment of TLE in the second half of the first decade of life (**Engel et al., 2012**).

The association between Hippocampal Sclerosis (HS) and epilepsy has been known for almost two centuries. Mesial Temporal Sclerosis (MTS) is a progressive disorder and seizures initially controlled with antiepileptic drugs can later become intractable in 60–90%. Although surgery is a proven therapy, only 50% of cases have sustained postoperative seizure freedom and surgery can have important adverse consequences (**O’Dell et al., 2012**).

Cases with intractable seizures due to unilateral MTLE are excellent candidates for surgical treatment and resective surgery achieves a short-term cure in up to 85% of cases and long-term cure in 57-66% of cases.

Unfortunately, up to 30% of temporal lobe epilepsy cases are unsuitable for surgery due to the bilateral nature of the disease or concerns for the risk of memory deficit, severe amnesia following the removal of the amygdalohippocampal complex and visual field defects, as well as cognitive impairment (**Min et al., 2013**).

The discovery of damage extending beyond the hippocampus in cases with MTLE also highlighted that regional brain damage in MTLE is more likely to involve structures within the limbic system, particularly regions that are anatomically and functionally related to the hippocampus. This observation led to the hypothesis that MTLE is a disease affecting not only the hippocampus but also involving a network of interrelated structures, such as the entorhinal and perirhinal cortices, thalamus, anterior cingulate and cortical association areas (**Bocti et al., 2003**).

# **AIM OF THE WORK**